New hope for long COVID heart sufferers: drug combo trial launches

NCT ID NCT05619653

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This study tests whether a combination of anti-inflammatory and heart-protecting drugs can reduce symptoms and heart damage in people with Long COVID who have ongoing heart inflammation. About 279 adults with heart inflammation seen on MRI will receive either the drug combo or a placebo for several months. The goal is to see if this treatment can improve heart function and reduce symptoms like chest pain and shortness of breath.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary โ€” we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LONG COVID are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

coronary microvascular disorder left ventricular failure long COVID-19 Microvascular Angina myocarditis pericarditis Vascular Remodeling vasculitis Ventricular Dysfunction, Left Ventricular Remodeling

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Institute for experimental and translational cardiovascular imaging

    Frankfurt am Main, Hesse, 60596, Germany

  • University Hospital Greifswald

    Greifswald, 17475, Germany

  • University Hospital Schleswig-Holstein, Campus KIEL

    Kiel, 24105, Germany

  • University Hospital Ulm

    Ulm, 89081, Germany

  • University Medical Centre Vienna

    Vienna, 1090, Austria